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Abstract
Background: Age-related neurodegenerative diseases share a number of important pathological features, such as
accumulation of misfolded proteins as amyloid oligomers and fibrils. Recent evidence suggests that soluble
amyloid oligomers and not the insoluble amyloid fibrils may represent the primary pathological species of protein
aggregates.
Results: We have produced several monoclonal antibodies that specifically recognize prefibrillar oligomers and do
not recognize amyloid fibrils, monomer or natively folded proteins. Like the polyclonal antisera, the individual
monoclonals recognize generic epitopes that do not depend on a specific linear amino acid sequence, but they
display distinct preferences for different subsets of prefibrillar oligomers. Immunological analysis of a number of
different prefibrillar Ab oligomer preparations show that structural polymorphisms exist in Ab prefibrillar oligomers
that can be distinguished on the basis of their reactivity with monoclonal antibodies. Western blot analysis
demonstrates that the conformers defined by the monoclonal antibodies have distinct size distributions, indicating
that oligomer structure varies with size. The different conformational types of Ab prefibrillar oligomers can serve as
they serve as templates for monomer addition, indicating that they seed the conversion of Ab monomer into
more prefibrillar oligomers of the same type.
Conclusions: These results indicate that distinct structural variants or conformers of prefibrillar Ab oligomers exist
that are capable of seeding their own replication. These conformers may be analogous to different strains of
prions.
Background
Many age-related degenerative diseases are characterized
by the accumulation of amyloid deposits derived from a
variety of proteins. There is conflicting evidence for the
role of insoluble fibrillar Ab deposits in Alzheimer’s dis-
ease (AD) pathogenesis. The extent of insoluble Ab pla-
que accumulation does not correlate well with the
severity of dementia in AD [1] and a significant fraction
of age matched, non-demented individuals have equiva-
lent amounts of Ab plaques as demented individuals. In
addition, some transgenic animals display cognitive defi-
cits prior to the onset of Ab plaque accumulation [2,3].
Soluble Ab levels correlate better with dementia than
insoluble, fibrillar deposits [4,5], suggesting that oligo-
meric forms of Ab may represent the primary toxic spe-
cies in AD. Indeed, soluble oligomers have been
implicated as primary causative agents in many different
degenerative diseases where the accumulation of large
fibrillar deposits may be either inert or protective
(reviewed in [6,7]).
Conformation dependent, aggregation specific antibo-
dies indicate that there are at least 3 structurally distinct
general classes of amyloid oligomers: prefibrillar oligo-
mers, fibrillar oligomers and annular protofibrils. Prefi-
brillar oligomers (PFOs) are kinetic intermediates that
occur at early times of aggregation and are recognized
by the polyclonal antibody, A11 [8]. Fibrillar oligomers
(FOs) appear to be small pieces of fibril protofilaments
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serum, OC [9,10]. A11 does not recognize amyloid
fibrils or monomers while OC does not recognize prefi-
brillar oligomers or monomers [9]. Annular protofibrils
(APFs) are ring shaped, pore-like structures that display
an epitope that is specifically recognized by aPF anti-
serum [11]. These three classes of amyloid oligomers
appear to be general and common to many different
types of amyloid forming proteins and peptides because
A11, OC and aAPF antibodies recognize generic epi-
topes that are displayed by their respective oligomers
when formed by many different peptides of varying
amino acid sequences.
Many amyloid fibril structures are known to be paral-
lel, in register b-sheets based on NMR and EPR spectro-
scopic studies (reviewed in [12,13]), Ab fibrils are
structurally polymorphic and this variation arises from
conformational differences in the folding of the parallel,
in register sheet [14-16]. These folding polymorphisms
are self propagating and give rise to differences in the
quaternary structure of the fibrils resulting in the assem-
bly of fibrils containing 2 or 3 protofilaments [14,16,17].
Yeast prions are also parallel, in register structures
[18,19] and exhibit remarkable phenotypic variants or
strain behavior that may be based on underlying struc-
tural variation of the type observed for amyloid fibrils
[20]. PFOs appear to be a class of amyloids that is struc-
turally distinct from amyloid fibrils based on the obser-
vation that they are recognized in a mutually exclusive
manner by the conformation dependent antibodies A11
and OC [9,10]. PFOs also lack strong spin-spin coupling
of paramagnetic spin probes that are characteristic of
parallel, in-register fibrils [10,21]. Since both of these
antibodies recognize generic epitopes that are formed by
many different amyloidogenic sequences, these differ-
ences are likely to be fundamental differences in the
organization of the polypeptides in the sheets, implying
that PFOs are not parallel, in-register structures that
have been established for amyloid fibrils. FTIR spectro-
scopy indicates that A11 positive PFOs may be antipar-
allel beta sheets, implying that they are not
intermediates on the pathway to the formation of paral-
lel, in-register fibrils [22]. It is not known whether the
PFO structures are polymorphic and display the same
types of structural variants that have been reported for
amyloid fibrils. Since A11 is polyclonal, it is not clear
whether its ability to recognize PFOs from many differ-
ent types of amyloids is a reflection of the commonality
of PFO structure or multiple individual antibodies in the
population that recognize different sequence specific
PFO epitopes.
We isolated a number of different rabbit monoclonal
antibodies (Mabs) specific for prefibrillar oligomers.
Here we report that these antibodies recognize generic
epitopes that are distributed among several prefibrillar
oligomer forming sequences and they display distinct
preferences for different protein sequences. In different
preparations of Ab prefibrillar oligomers, the monoclo-
nals recognize distinct subtypes, indicating that struc-
tural “strains” of prefibrillar oligomers exist. These
strains are capable of propagating by seeding the con-
version of Ab monomer into PFOs of the same type.
These results demonstrate that amyloid oligomers are
more structurally diverse than was previously known
and raise the questions of which of these structural var-
i a n t si sm o r ec l o s e l ya s s o c i ated with disease pathogen-
esis and whether the variation contributes to disease
heterogeneity.
Results
Prefibrillar oligomer specific monoclonals
We made prefibrillar oligomer specific monoclonal anti-
b o d i e su s i n gt h es a m es t r a t e g yw ee m p l o y e dt om a k e
the A11 polyclonal by vaccinating rabbits with Ab40
covalently coupled to colloidal gold particles via a car-
boxyl terminal thiol [8]. Rabbits were chosen primarily
because we had limited success in making A11-like
monoclonals in mice. In 4 independent fusions using 4
different strains of mice, the only antibodies specific for
prefibrillar oligomers were IgMs. The rabbit monoclo-
nals we obtained are predominantly IgG and they have
the additional advantage that they are the same species
of antibodies as the polyclonal A11. We selected 6 dif-
ferent clones based on their differential immunoreactiv-
ities on ELISA (data not shown) and dot blot (Figure 1).
Four of the 6 clones recognize generic epitopes in sev-
eral different PFO-forming sequences, including Mabs
55, 118, 204 and 205, which are all IgG1. These antibo-
dies display distinct preferences for different subsets of
PFOs, suggesting that the broader range of A11 immu-
noreactivity is due to the presence of multiple individual
antibody specificities. Mab204 appears to have the
broadest generic reactivity because it reacts strongly
with all PFOs tested except IgG light chain. These
results demonstrate that individual clones are capable of
recognizing epitopes that are generically distributed
among PFOs formed by different sequences and that the
different antibodies recognize different epitopes that are
differentially displayed on PFOs formed from different
sequences. Mab201 appears to be both conformation
and sequence specific because it recognizes only Ab pre-
fibrillar oligomers. This demonstrates that some of the
monoclonals are sequence specific and do not recognize
generic epitopes. Antibody 121 recognizes Ab fibrils and
not prefibrillar oligomers, similar to OC. Both Mab201
and 121 are IgM class antibodies. Because the hybri-
doma cells secrete very low amounts of IgM, further
work was concentrated on the monoclonal IgGs.
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and light chains and compared their amino acid
sequences (Figure 2A, B). These results indicate that
the primary sequences of the 6 monoclonal antibodies
are distinct. Mab121 and 201 share a common kappa
chain, even though Mab121 is specific for Ab fibrils,
while Mab201 is specific for prefibrillar oligomers.
This indicates that the heavy chain is responsible for
distinguishing these two conformations of aggregates
in 121 and 201. No heavy chain sequence was obtained
for 201.
Monoclonal antibodies identify distinct types of Ab
prefibrillar oligomers
When we examined a large number of A11 positive, Ab
prefibrillar oligomer preparations with the monoclonal
IgG antibodies, we observed that some preparations of
A11 positive oligomers do not react with some of the
monoclonal antibodies, indicating that there are immu-
nologically distinct subclasses of Ab prefibrillar oligo-
mers (Figure 3). Mab 118 stains both Ab40 and Ab42
prefibrillar oligomers prepared at pH 2.5, but does not
stain prefibrillar oligomers prepared in Hepes buffered
saline (HBS) or phosphate buffered saline (PBS) at pH
7.4 (Figure 3A), suggesting that the epitope for Mab118
is specific to oligomers prepared at pH 2.5. We also
examined a number of different prefibrillar oligomer
preparations that were all prepared by the same method:
dilution from HFIP solution and incubation in water,
pH 2.5. These preparations were made from the same
lot of peptide using the same protocol on different days
over a period of approximately one year. Surprisingly,
Mab204 and Mab205 display distinct preferences for the
different preparations of Ab42 oligomers, even though
they are all A11 positive (Figure 3B). The reason for the
lack of reproducibility in oligomer immunoreactivity in
Figure 1 Dot blot analysis of monoclonal antibody specificity.
Nitrocellulose strips containing 1 ug spots of Ab40 monomer, PFOs
and fibrils and prefibrillar oligomers prepared from a-synuclein,
immunoglobulin light chain, prion 106-126 peptide, KK(Q40)KK
peptide, and calcitonin were probed with the monoclonal
antibodies and with A11 polyclonal and 6E10 control antibodies.
A11 stains all prefibrillar oligomers samples, while 6E10 recognizes
only samples containing Ab. The individual monoclonal antibodies
only recognize Ab PFOs and not Ab monomer or fibril samples, but
display distinct preferences for other types of PFOs. Mab204 displays
the broadest reactivity, recognizing all PFOs except for light chain,
while Mab 201 is the most restrictive reacting with only Ab PFOs.
Figure 2 Sequence comparison of monoclonal antibodies.F i v e
monoclonal antibody mRNAs were cloned and sequenced.
Alignment of heavy chain (A.) and light chain (B.) variable region
amino acid sequences by the Clustal V method is shown. Regions
of identical sequence are shown in red, while highly variable
regions are shown in blue. Regions of increasing similarity are
shown in colors of increasing wavelength.
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known. These results indicate that there are structural
polymorphisms within the class of A11 immunoreactive
Ab prefibrillar oligomers that can be distinguished by
the monoclonal antibodies. We have also prepared A11
positive Ab oligomers that do not react with any of the
monoclonal antibodies we have (Figure 3B and data not
shown), indicating that there are antibodies in polyclo-
nal A11 that are not represented in the clones we
obtained. While the epitope recognized by M118
appears to be pH dependent, it is not yet clear why the
immunoreactivities of Mab204 and Mab205 vary
because they react differentially with different prepara-
tions of Ab oligomers prepared by the same methods.
The variation appears to occur randomly.
Different types of oligomers have distinct size
distributions
Prefibrillar oligomers were prepared from Ab40 under
two different conditions and analyzed by Western blot-
ting along with freshly prepared monomer. The immuno-
blots indicate that the monoclonal antibodies recognize
distinct size distributions of oligomers (Figure 4A). A11
recognizes a broad range of sizes from a putative dimer
of 10 kDa to large oligomers of approximately 240 kDa.
The individual monoclonals recognize subsets of the
bands stained by A11. Mab55 recognizes a ladder of
bands ranging from approximately 12 kDa up to approxi-
mately 56 kDa (Figure 4A). The apparent step size for
the ladder stained by antibody 55 is approximately 2,250
Da. Since the molecular mass of Ab40 is 4328 Da, this
suggests that the oligomers migrate artifactually fast on
SDS gels and that they contain approximately twice the
number of peptide chains than their migration on SDS
gels would suggest. A similar ladder-like distribution of
Ab oligomers is also observed with A11[10] although it is
not apparent on this blot (see below). Mab118 also stains
a 56 kDa band but does not detectably stain a dimer
band like Mab 55. Mabs204 and 205 stain a broad band
between 35 kDa and 45 kDa. The staining of this band by
Mab205 is much more intense than that of Mab204.
None of the conformation dependent monoclonals or
polyclonal antibodies recognize the low molecular weight
bands in freshly dissolved Ab40 preparations (labeled
“monomer”), which are recognized by the sequence spe-
cific mouse monoclonal antibody 6E10 (Figure 4A). Oli-
gomer preparation 1 contains high molecular weight
material migrating at the top of the gel that is stained by
the fibril specific polyclonal, OC and by 6E10. This mate-
rial is commonly observed in fibril preparations, but it is
not stained by A11 or any of the A11-like monoclonal
antibodies, consistent with the observation that these
antibodies do not recognize fibrils on dot blots or ELISA.
Additionally, oligomer preparation 2 contains low mole-
cular weight FOs recognized by OC as previously
described [9,10]. These results indicate that different
sized PFOs display unique epitopes associated with dis-
tinct size distributions of oligomers that are a subset of
the prefibrillar oligomers stained by the polyclonal A11.
Figure 3 Monoclonal antibodies distinguish conformational
variants of Ab PFOs. A.A b40 (40) and Ab42 (42) were incubated
under three different conditions: HEPES buffered saline pH7.4, water
pH 2.5 or PBS pH 7.4. Monomer samples were spotted at time zero,
while prefibrillar oligomers and fibrils were spotted at 72 and 240
hours of incubation respectively. All of the oligomer samples stain with
A11, but M118 only reacts with the Ab samples prepared at pH 2.5. B.
Four different samples of prefibrillar oligomers were prepared in water
pH 2.5 and stained with A11, M204 and M205. All samples stain with
A11 (top row). Sample 1 stains with both 204 and 205 antibodies while
sample 2 stains with only M204, sample 3 stains only with M205 and
sample 4 stains with neither monoclonal antibody.
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bodies is the same for the two different preparations of
prefibrillar oligomers in Figure 4A, however, Mab204
also stains high molecular weight oligomers in PFOs
prepared by dilution of HFIP stock Ab42 solutions in
distilled water and incubated at pH 2.5 (Figure 4B). We
also examined the size distribution of PrP 109-149 and
a-synuclein PFOs. The size distribution of A11
immunoreactivity for Ab42 is similar to that of Ab40
(Figure 4A), while PrP109-149 displayed a ladder-like
pattern from approximately 10 kDa to 100 kDa and
a-synuclein PFOs ran as a broad band between 36 kDa
and 100 kDa. Mab 204 stained high molecular mass
bands in Ab42 PFOs and a 100 kDa band in PrP109-
149 PFOs, but did not stain a-synuclein oligomers on
Western blots, although Mab204 stained a-synuclein on
Figure 4 Western blot analysis of monoclonal antibody PFO specificity. A. Two different Ab40 PFOs samples (O1 and O2) and Ab40
“monomer” (M) were prepared as described in Methods. None of the PFO specific monoclonal antibodies stain Ab monomer, although the
“monomer” sample is recognized by the 6E10 control antibody. Different Mabs stain distinct size distributions of Ab PFOs. OC polyclonal sera
stains high MW bands in oligomer preparation O1 and low MW bands in preparation O2. B. PFO specific monoclonal antibodies recognize
soluble oligomers of Ab42 and other types of amyloids. Soluble oligomers were prepared from Ab, PrP 109-149 and a-synuclein as described in
Methods. Aggregates were analyzed by Western blot with 6E10, A11, and monoclonal antibodies 55, 204, and 205. 6E10 only recognizes Ab
peptide. A11 detects oligomers of different sizes that are formed by Ab and other types of amyloids. Monoclonal antibodies preferentially
recognize different subsets of A11 positive oligomers.
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immunoreactivity is not yet clear, but either the a-synu-
clein oligomers recognized by Mab204 are sensitive to
SDS denaturation or there is conformational variability
in these two different a-synuclein oligomer preparations
as we have observed for Ab (Figure 3B). Mab55 stained
a 10 kDa Ab42 band and a ladder-like series of bands in
PrP109-149 that are similar to the pattern observed for
Ab40 (Figure 4A). Mab205 stained a broad band
between approximately 25-45 kDa in Ab42, PrP109-149
and a-synuclein. This identical size distribution of the
a-synuclein Mab205 immunoreactive species is surpris-
ing in view of the fact that the molecular mass of
a-synuclein is approximately 3-fold higher than Ab42 or
PrP 109-149. No staining was observed with Mab118
(data not shown). While Mabs55 and 205 stain similar
patterns of bands in all samples, the size distribution of
Mab204 immunoreactivity varies between Ab40 and
Ab42 samples.
Oligomers seed their own replication
Western blotting results with the monoclonal IgGs sug-
gest that there are at least two distinct types of A11
immunoreactive Ab oligomers with different size distri-
butions that occur randomly in oligomer preparations: A
ladder-like series ranging in size from approximately
10 kDa to 56 kDa that is recognized by Mab55 and a
broad band between 35 kDa and 45 kDa that is recog-
nized by Mab205. We investigated whether these distinct
oligomer types can seed the conversion of Ab monomer
into oligomers of the same immunological type and size
distribution. The ladder-like oligomers seed the conver-
sion of monomer into the same type of oligomers as indi-
cated by the acceleration of the formation of A11 positive
oligomers compared to unseeded monomer controls
(Figure 5A). The rate of formation is slow compared to
fibril and fibrillar oligomer seeded polymerization [10],
reaching a maximum in approximately 8 days. However,
no A11 oligomers are observed under these conditions in
the unseeded samples. Similar results were obtained
when Ab40 monomer was seeded with 1% of a prepara-
tion of Mab205 positive Ab40 prefibrillar oligomers that
run as a broad band between 35 - 45 kDa (Figure 5B).
The presence of seeds promotes the formation of
Mab205 positive oligomers compared to monomer sam-
ples incubated in the absence of seeds. Ab40 and Ab42
35 - 45 kDa oligomers also seeded the oligomerization of
Ab42 to form A11 positive oligomers that run as a broad
band between 35-45 kDa (Figure 5C). The absence of
staining of other size bands by A11 indicates that the
seeding results in the template specific assembly of a
homogeneous population of 35-45 kDa oligomers.
Fibrils and fibrillar oligomers spontaneously form in
solutions of Ab40 monomer in H2O at pH 7.4 [10].
These fibrillar aggregates are recognized by OC polyclo-
nal antiserum, but not by A11[9]. We examined whether
seeding these solutions with PFOs can compete for fibril
and fibrillar oligomer formation (Figure 5D). The addi-
tion of 1% PFO seeds completely suppresses the devel-
opment of OC positive fibrils and fibrillar oligomers
over two days of incubation. Western blot analysis of
the samples showed that A11 positive PFOs developed
in this sample rather than OC positive fibrils and FOs
(data not shown). These results indicate that the pre-
s e n c eo fP F O sa l t e r st h ea g g r egation pathway to favor
the formation of PFOs rather than FOs that would nor-
mally form in the absence of PFO seeds.
Oligomer specific monoclonal antibodies do not stain
plaques
We also investigated whether the monoclonal IgGs can
detect the accumulation of PFOs in human AD brain
and Tg2576 and 3xTg-AD transgenic mouse brains. No
specific staining of plaque deposits was observed by
immunohistochemistry in human AD brain (Figure 6)
or transgenic mouse brain (data not shown), indicating
that the Mabs do not stain plaques, consistent with
their lack of reactivity with amyloid fibrils. It is not yet
clear whether the oligomers recognized by these antibo-
dies are absent from human AD or Tg mouse brain tis-
sue. The antibodies exhibit low background reactivity on
tissue, indicating that they do not detectably cross react
with normal proteins. Further experiments with higher
resolution and sensitivity, such as immuno electron
microscopy and immunoprecipitation will be necessary
to determine whether these oligomers are detectable
in vivo.
Discussion
The prefibrillar amyloid oligomer specific monoclonal
antibodies that we have cloned display the canonical fea-
tures of A11, the corresponding polyclonal antiserum
from which they are derived. They recognize epitopes
that are specifically associated with prefibrillar oligomers
and do not recognize fibrils, fibrillar oligomers, mono-
mer or natively folded proteins. Like A11, the monoclo-
nal IgGs recognize generic epitopes that are displayed
on PFOs from several different amyloidogenic
sequences, but one of the IgM antibodies, Mab201,
recognizes only Ab PFOs, indicating that some of the
epitopes are both conformation and sequence specific.
Unlike A11, which displays no obvious sequence prefer-
ence, the individual monoclonals display distinct prefer-
ences for different types of oligomers. All of the
monoclonal IgGs react strongly with Ab PFOs because
this preparation was used in the primary screening pro-
tocol to select the immunopositive hybridomas. Mab55
appears to be the most selective, because it only reacts
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appears to have the broadest specificity as it recognizes
all types of PFOs strongly except light chain.
The distinct PFO preferences displayed by the mono-
clonal IgGs would appear to indicate that the antibodies
prefer PFOs formed by certain sequences and not
others, but further analysis indicates that conformational
polymorphism within a sequence is another plausible
explanation. The surprising finding is that the same type
of immunological variation is observed in different pre-
parations of Ab. This indicates that the different epi-
topes can be displayed or not by the same sequence
depending on the conformation of the peptide and sug-
gests that the Ab sequence can adopt a number of dis-
tinct conformations that may be analogous to the
structural polymorphisms in different strains of the
yeast prion Sup35 [23]. The variation in detection of Ab
PFOs by Mabs204 and 205 indicates that there are at
least three distinct types of PFOs: Mab204+, Mab205+
and a type that is negative for both Mabs that is recog-
nized by A11. The fact that none of the Mabs reacted
with this latter preparation of Ab PFOs suggests that
some of the antibodies represented in A11 have yet to
be cloned.
One of the key properties of yeast prions is the ability
to replicate and propagate in a template specific fashion
[24], so we investigated the ability of Ab PFOs to seed
the conversion of Ab monomer in a template specific
fashion. We found that both the ladder like Mab55 posi-
tive PFOs and the 36 kDa Mab205 positive PFOs are
Figure 5 Prefibrillar oligomers seed prefibrillar oligomer formation from monomer. A. The presence of a small amount of ladder like 10 -
56 kDa PFO seeds (prepared by dilution of NaOH stock solutions of Ab40 into10 mM phosphate buffer pH 7.4), accelerates oligomer formation
and gives rise to oligomers that stain with A11. No PFO immunoreactivity is observed in the non-seeded samples under these conditions. B.
Mab 205 positive 35 - 45 kDa PFOs seed their own formation from Ab40 monomer. C. Mab 205 35 - 45 kDa Ab40 and Ab42 PFOs seed the
formation of A11 positive 35 - 45 kDa oligomers from Ab42 monomers. Only the 35 - 45 kDa band is detected by A11, indicating that other
sizes of oligomers are not formed. D. Seeding with PFOs suppresses the formation of fibrillar oligomers. In comparison, FOs spontaneously form
in unseeded samples.
Figure 6 A11-like monoclonal antibodies do not stain amyloid
plaques in human AD brain. Sections of frontal cortex
(Broadman’s area 11) were stained with Mabs 55, 18, 204 and 205
and 6E10 as a control. The bar indicates 200 μm.
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into the same type of PFOs used to seed the reaction,
indicating that PFOs also seed in a template specific
fashion. Fibrils and fibrillar oligomers are also capable of
seeding the conversion of monomer in a template speci-
fic fashion [10,14]. This indicates that several distinct
types of Ab oligomers exist that have structurally dis-
tinct lattices that can facilitate the addition of mono-
mers by intermolecular hydrogen bonding to the ends
of the beta sheets. The newly added Ab peptide adopts
the same folded conformation as the peptides serving as
the template beneath it extending the intermolecularly
hydrogen bonded b sheet lattice. The stability of the lat-
tice appears to determin et h er a t ea tw h i c ht h eA b oli-
gomers replicate as it does for yeast prions [10]. Ab40
fibrillar oligomers replicate maximally in approximately
2 hours [10], while Ab40 PFOs take several days to seed
the conversion of monomer into PFOs.
The observation of structurally distinct strains of Ab
prefibrillar oligomers that display different size distribu-
tions on Western blots may provide some insight into
the structural organization of this class of oligomers.
T h ef a c tt h a tn o n eo ft h eP F Os p e c i f i cM a b sr e c o g n i z e
fibrillar structures that are known to be parallel
b strands in exact register suggests that PFOs are not
parallel beta sheets. The generic epitopes associated
with parallel b sheet fibrils are recognized by OC poly-
clonal antibodies that are specific for fibrils and fibrillar
oligomers and do not recognize PFOs [9,10]. A molten
globule like intermediate has been proposed for amyloid
aggregation [25-27]. In computer simulations of Ab pep-
tide aggregation, monomers were observed to rapidly
coalesce into a “molten oligomer” ensemble of disor-
dered peptides held together by predominantly hydro-
phobic interactions and at later times evolve into
intermolecularly hydrogen bonded oligomers [28]. It
seems unlikely that an ensemble of disordered molten
structures would display unique epitopes that the anti-
bodies could discriminate, so this class of oligomer
structure does not seem to have the requisite structural
diversity to explain all of the types of oligomers
observed here. However, the disordered molten oligomer
could constitute one of the oligomer subtypes that are
not recognized by the conformation dependent antibo-
dies. It has also been suggested that A11 positive PFOs
are anti-parallel b sheets, based on FTIR spectroscopy
[22]. This model provides a facile explanation for the
difference between fibrils and fibrillar oligomers, which
are parallel beta sheets and PFOs, but it raises the ques-
tion of the structural basis for the conformational poly-
morphisms and the molecular nature of the generic
epitopes. If PFOs are ordered, antiparallel b sheets, then
the strands would alternate, giving rise to a linear pat-
tern of alternating amino acid side chains displayed on
the surfaces of the sheet. These tracts of alternating side
chains could constitute the generic epitopes for the A11
like Mabs, similar to the fashion in which the homoge-
neous amino side chain tracts may constitute the gen-
eric fibril epitopes on parallel in register b sheets.
Depending on the folding of the sheet, these epitopes
m a yb ee i t h e rh i d d e no re x p o s e do nt h es u r f a c eo ft h e
sheet, which could explain the diverse pattern of immu-
nological recognition of Ab PFOs by the Mabs.
Alzheimer’s disease is known to be clinically and
pathologically heterogeneous [29]. Moreover, the role of
amyloid in disease is inconsistent with some cognitively
normal individuals having large amounts of amyloid pla-
ques, suggesting that not all amyloid is pathologically
significant [30]. The findings that amyloid fibrils [14,16]
and prefibrillar oligomers display structural heterogene-
ity suggests that these polymorphisms may underlie the
disease heterogeneity and predict that the different
structural variants may have distinct toxic activities and
pathological significance.
Methods
Antibody production
Rabbit monoclonal antibodies were produced under a
contract with Epitomics, Incorporated, Burlingame, CA.
New Zealand white rabbits were immunized subcuta-
neously with Ab40-colloidal gold oligomer mimics at a
0.25 mg Ab dose bit and boosted seven times with the
same amount at 3 weeks intervals. The titer and specifi-
city of the immune response was determined by ELISA
and dot blot analysis as previously described using
serum collected after the third and sixth boosts [8]. The
ELISA plates and dot blot strips were coated with 50 ng
of 5 different samples: Ab monomer, Ab PFOs, Ab
fibrils, a-synuclein PFOs and islet amyloid polypeptide
(IAPP) PFOs. Rabbits demonstrating a serum titer ≥ 0.3
OD at dilution of 1:64,000 were used as a source of
splenocytes for fusion. A11 and 6E10 antibodies were
used as positive controls and preimmune serum was
used as negative control.
Hybridoma screening
96 hybridoma pools out of a total of 1920 were selected
that were positive for Ab42 PFOs by ELISA using plates
coated with 50 nm of Ab42 PFO. Of this set of 96
pools, 36 pools displayed aggregation state specificity for
Ab42 PFOs were selected for further analysis by ELISA
using plates coated with Ab monomer, Ab PFO, Ab
fibrils, a-synuclein PFO and IAPP PFO, and dot blotting
against Ab monomer, PFOs, Ab fibrils and alpha synu-
clein, light chain, PrP 106-126, KKQ40KK and calcitonin
oligomers. Based on these analyses, 6 clones displaying
unique immunoreactivities were selected for cloning: 55,
118, 121, 201, 204 and 205.
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Lyophilized peptide (Ab 40 or 42) was resuspended in
50% acetonitrile/water mixture and relyophilized. Solu-
ble oligomers were prepared by dissolving 0.3 mg of the
peptide in 250 μl hexafluoroisopropanol (HFIP) and
incubating for 10-20 min at room temperature. The
resulting solution was diluted to 70 μMi nH 2O contain-
ing 0.02% NaN3 in a siliconized Eppendorf tube as pre-
viously described [8]. In some experiments, the HFIP
stock solution was diluted in Hepes buffered saline, pH
7.4 (HBS) or phosphate buffered saline pH 7.4 (PBS)
containing 0.02% NaN3. The samples were then stirred
at 500 RPM using a Teflon-coated micro stir bar for at
room temperature. Aliquots were taken at 0-240 hr
intervals for testing with anti-oligomer antibody A11 [8].
Alternatively Ab40 oligomers were prepared by dissol-
ving the lyophilized peptide (0.3 mg) at a concentration
of 2.5 mM in 100 mM NaOH. The oligomerization
reaction was initiated by diluting the stock solution to
70 μMi n1 0m Mp h o s p h a t eb u f f e r ,p H7 . 4 ,0 . 0 2 %
NaN3. The monomer was prepared by dissolving the Ab
40 (0.1 mg) in 30 μl of 10%SDS, heating at 90°C for 5
minutes and diluted to 45 μMi nH 2O. PrP 109-149,
and a-synuclein were solubilized in HFIP (hexafluoro-2-
propanol) at a concentration of 420 uM for 25 minutes
at room temperature. Then the peptide solution was
diluted into ddH2O, pH 2.5, 0.02% NaN3 at 70 μMa n d
stirred at 500 rpm. with a Teflon coated micro stir bar
for 2 days. Caps with three 18 gauge needle holes were
used to allow slow evaporation of HFIP.
Western and dot blotting
Samples containing 4 μgo fA b42, PrP 109-149, and
a-synuclein were dissolved in SDS treatment buffer,
boiled for 5 min, and electrophoresed on 10-20% Tris-
HCl (Bio-Rad) gels. Proteins were electrophoretically
transferred onto nitrocellulose membranes and devel-
oped with 6E10 (0.1 ug/ml), A11 (1.05 ug/ml), and
monoclonal antibodies 48 (1.15 ug/ml), 55 (0.8 ug/ml),
204 (1.05 ug/ml), and 205(0.2 ug/ml). Dot blots and
Western blots were performed as previously described
[10]. For Western blots, samples containing 4 μgo f
Ab40 were dissolved in SDS treatment buffer, boiled for
5 min, and electrophoresed on 4-20% Tris-HCl (Bio-
Rad) gels. Proteins were electrophoretically transferred
onto nitrocellulose membranes and developed with con-
formation-specific antibodies. For dot blots, 0.36 ug of
protein was spotted. The concentration of primary anti-
bodies were 6E10 (0.1 μg/ml/ml), OC (0.2 μg/ml), A11
(1.05 μg/ml), 48(1.15 μg/ml), 55(0.8 μg/ml), 118 (0.2 μg/
ml), 204 (1.05 μg/ml) and 205 (0.2 μg/ml). The mem-
branes were then incubated with anti-rabbit IgG conju-
gated with horseradish peroxidase (1:10,000, Jackson) at
room temperature for 1 h. The blots were developed
with Super signal West pico chemiluminescence kit
from Thermo Scientific.
Oligomer seeding
Ab40 peptide (0.05 mg) was dissolved in sodium hydro-
xide (0.1 M, 12 μl) and incubated for 30 min. The solu-
tion was then diluted with sodium phosphate buffer (10
m M ,p H8 . 0 ,5 0 0μl), and then seeded with previously
prepared A11-positive oligomers (10 μl, 0.2 mg/ml, 4%
by weight). The reaction mixture was incubated at 24°C
for 2-10 days and assayed for antibody reactivity with
Western and dot blots. The diluted Ab40 solution in
the absence of added oligomers was used as a control.
Immunohistochemistry
Fixed brain tissues (prefrontal cortex) from AD patients
were sectioned (50 μm) with a vibratome. Coronal sec-
tions were collected in PBS (containing 0.02% sodium
a z i d e )a n ds t o r e da t4 ° Cp r i o rt os t a i n i n g .T os t a i nf o r
Ab plaques, sections were immersed in 70% formic acid
for 5 min. Endogenous peroxidase in tissue was blocked
by treating with 3% H2O2 in PBS for 10 min at room
temperature. Nonspecific background staining was
blocked by 1 h incubation in 2% BSA, 0.3% Triton
X - 1 0 0( T X )a tr o o mt e m p e r a t u r e .T i s s u e sw e r ei n c u -
bated with primary antibodies 6E10 (0.2 μg/ml), 55(3.2
μg/ml), 118(1.6 μg/ml), 204 (4.8 μg/ml) and 205 (4 μg/
ml) for 48 hrs at 4°C, rinsed 3 times with PBS,0.1% TX,
followed by biotinylated secondary antibodies (anti-
mouse for 6E10 and anti-rabbit for rabbit antibodies),
detection with an ABC peroxidase kit, and visualization
with a 3,3’-diaminobenzidine (DAB) substrate kit
(Vector, Burlingame, CA).
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